top of page

Selected Research Publications

  • Han, H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022). Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.

      Cell Reports 39, 110595. (In press, April 5th, 2022) 

  • Chen G*, Zhou H*, Liu B, Wang Y, Zhao J, Giancotti FG#, Long J.#. A Heterotrimeric SMARCB1-SMARCC2 Subcomplex is Required for the Assembly and Tumor Suppression Function of the BAF Chromatin-remodeling Complex. Cell Discov. 2020; 6:66.

      [*equal contributions; #co-corresponding authors] PMID: 33024572

  • Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, Rumandla A, Gurrapu S, Chakraborty G, Su J, Yang G, Liang X, Wang G, Rosen N, Scher H, Ouerfelli O, Giancotti FG. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.

      Cancer Cell, 2019; 36(2):139-155.  PMID: 31327655

  • Er EE, Valiente M, Ganesh K, Zou Y, Agrawal S, Hu J, Griscom B, Rosenblum M, Boire A, Brogi E, Giancotti FG, Schachner M, Malladi S, Massagué J. Pericyte-Like Spreading by Disseminated Cancer Cells Activates YAP and MRTF for Metastatic Colonization.

     Nat. Cell Biol., 2018; 20:966-978. PMID: 30038252

  • Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss- driven tumorigenesis.

     Mol. Cancer Ther. 2017; 16:1693-1704.

     Editorial by Janse van Rensburg and Yang in J. Thorac Dis. 2017; 9(10):3533-3536]. 

     PMID:  28468780

  • Gao H, Chakraborti G, Zhang Z, Akalay I, Gadiya M, Gao Y, Sinha S, Hu J, Jiang C, Akram M, Brogi E, Leitinger B, Giancotti FG. Multi-organ site metastatic reactivation mediated by non-canonical Discoidin Domain Receptor 1 signaling.

      Cell 2016; 166:47-62. DOI: 10.1016/j.cell.2016.06.009

  • Garcia-Rendueles MER, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar S, Viale A, Heguy A, Huberman KH, Giancotti FG, Ghossein R, Fagin JA. NF2 loss promotes RAS- induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition.

      Cancer Discov. 2015; 5:1178-1195. DOI: 10.1158/2159-8290.CD-15-0330

  • Okada T*, Esposito I*, Sinha S*, Schiavon G, Lopez-Lago MA, Su W, Pratilas CA, Abele C, Hernandez J, Ohara M, Okada M, Viale, A, Heguy A, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG. The Rho-GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signaling.

      Nat. Cell Biol. 2015; 17:81-94 [Editor’s Choice in Science Signaling]. DOI: 10.1038/ncb3082

  • Gao H, Chakraborty G, Lee-Lim A, Mavrakis KJ, Wendel H-G, Giancotti FG. Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation.

      Proc. Natl. Acad. Sci. USA 2014; 111:16532-165 37. DOI: 10.1073/pnas.1403234111

  • Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanneman O, Zhou P, Karajannis M, Giancotti FG. Merlin/NF2 loss- driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus.

      Cancer Cell 2014; 26:48-60. DOI: 10.1016/j.ccr.2014.05.001

  • Yoshioka T*, Otero J*, Chen Y, Kim YM, , Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. Integrin  β4 signaling induces expansion of prostate tumor progenitors.

       J. Clin. Invest. 2013; 123:682-699 [*equal contributions; Commentary by Wicha in the same issue].         DOI: 10.1172/JCI60720

  • Gao H, Chakraborty G, Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites.

      Cell 2012; 150:764-779. DOI: 10.1016/j.cell.2012.06.035

  • Li W*, You L*, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus.

      Cell 2010; 140:477-490 DOI: 10.1016/j.cell.2010.01.029

  • Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor NF2/Merlin constitutively activates integrin-dependent mTORC1 signaling.

      Mol. Cell. Biol. 2009; 29:4235-4249. DOI: 10.1128/MCB.01578-08

  • Pylayeva Y, Gillen KM, Gerald W, Beggs, HE, Reichardt, LF, Giancotti FG. Ras- and PI-3K-dependent mammary tumorigenesis in mice and humans require Focal Adhesion Kinase signaling.

      J. Clin. Invest. 2009; 119:252-266. DOI: 10.1172/JCI37160

  • Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG.  β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.

      Cell, 2006; 126:489-502 [Preview by Muthuswamy in Cell 126:443-445, 2006;

      DOI: 10.1016/j.cell.2006.05.047

  • Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane.

      J. Cell Biol. 2005; 171:361-371. DOI: 10.1083/jcb.200503165

  • Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin  β4 signaling promotes tumor angiogenesis.

     Cancer Cell 2004; 6:471-483. DOI: 10.1016/j.ccr.2004.09.029

  • Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti FG, Werb Z, Bissell MJ.  β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

      Cancer Cell 2002; 2:1-12. DOI: 10.1016/s1535-6108(02)00125-3

  • Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, Giancotti FG. Integrin-specific control of cell cycle progression mediated by Rac.

       Mol. Cell 2001; 8:115-127 [Previews by Ridley, A.J. in Dev. Cell 1(2):160-161, 2001]. 

       DOI:  10.1016/s1097-2765(01)00285-4

  • Barberis L, Wary, KK, Liu, F, Hirsch, E, Brancaccio, M, Altruda, F, Tarone, G, Giancotti, FG. Distinct roles of the adaptor protein Shc and Focal Adhesion Kinase in integrin signaling to ERK. J. Biol. Chem. 2000; 275:36532-36540. DOI:  10.1074/jbc.M002487200

  • Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. Integrin-mediated activation of FAK is required for signaling to JNK and progression through the G1 phase of the cell cycle.

      J. Cell Biol. 1999; 145:1461-1469. DOI: 10.1083/jcb.145.7.1461

  • Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth.

      Cell 1998; 94:625-634. DOI: 10.1016/s0092-8674(00)81604-9

  • Murgia C, Blaikie P, Dans M, Kim N, Petrie H, Giancotti FG. Cell cycle and adhesion defects in mice carrying a targeted deletion of the integrin b4 subunit cytoplasmic domain.

      E.M.B.O. J. 1998; 17:3940-3951. DOI: 10.1093/emboj/17.14.3940

  • Wary KK, Mainiero F, Isakoff S, Marcantonio EE, Giancotti FG. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression.

      Cell 1996; 87:733-743. DOI: 10.1016/s0092-8674(00)81392-6


  • Mainiero F, Pepe A, Spinardi L, Wary KK, Ammad M, Schlessinger J, Giancotti FG. Signal transduction by the a6b4 integrin: distinct b4 sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes.

      E.M.B.O. J. 1995; 14:4470-4481. PMID: 7556090

  • Giancotti FG, Ruoslahti E. Elevated levels of the a5b1 fibronectin receptor suppress the transformed phenotype of CHO cells.

      Cell 1990; 60:849-859. DOI: 10.1016/0092-8674(90)90098-y

  • Giancotti FG, Comoglio PM, Tarone G. Fibronectin-plasma membrane interaction in the adhesion of haemopoietic cells.

      J. Cell Biol. 1986; 103:429-437. DOI: 10.1083/jcb.103.2.429

Selected Review Publications

  • Cooper, J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance.

      Cancer Cell 2019; 35(3):347-367. DOI: 10.1016/j.ccell.2019.01.007

  • Laudato S, Aparicio A, Giancotti FG. Clonal evolution and epithelial plasticity in the emergence of AR-independent prostate carcinoma.

      Trends in Cancer, 2019; 5(7):440-455. DOI: 10.1016/j.trecan.2019.05.008

  • Giancotti FG. Mechanisms governing metastatic dormancy and reactivation.

      Cell 2013; 155:750-764. DOI: 10.1016/j.cell. 2013.10.029

  • Ladanyi M*, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti FG*. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

      Clin. Cancer Res. 2012; 18:4485-4490. DOI:  10.1158/1078-0432.CCR-11-2375

  • Giancotti FG. Targeting integrin  β4 for cancer and anti-angiogenic therapy.

      Trends Pharm. Sci. 2007: 28:506-511. DOI:  10.1016/

  • Okada T., You L, Giancotti FG. Shedding light on Merlin’s wizardry.

      Trends Cell Biol. 2007; 17:222-229. DOI:  10.1016/j.tcb.2007.03.006

  • Guo W, Giancotti FG. Integrin signaling during tumour progression.

      Nat. Rev. Mol. Cell. Biol. 2004; 5:816-826. DOI:  10.1038/nrm1490

  • Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein tyrosine kinase signaling.

      Annu. Rev. Cell Dev. Biol. 2003; 19:173-206. DOI: 10.1146/annurev.cellbio.19.031103.133334

  • Giancotti FG, Ruoslahti E. Integrin signaling.

      Science 1999; 285:1028-1032.

      A full list of  published work is found in below link

bottom of page